ANI Pharmaceuticals Reports Record Full Year and Fourth Quarter 2018 Results and Provides 2019 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to ANI Pharmaceuticals Reports Record Full Year and Fourth Quarter 2018 Results and Provides 2019 Guidance
February 28, 2019 7:42 AM EST
Raymond James analyst Elliot Wilbur raised the price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $73.00 (from $63.00) while maintaining a Strong Buy rating following another strong quarter.
Wilbur said they believe the outperformance in 4Q18 as well as solid initial 2019 guidance... More
February 27, 2019 8:34 AM EST
ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $1.32, $0.08 better than the analyst estimate of $1.24. Revenue for the quarter came in at $57.1 million versus the consensus estimate of $53.48 million.
For the fourth quarter 2018:
Record net revenues of $57.1 million, an increase of 21% versus 2017GAAP net income of $5.4 million and diluted GAAP earnings per share of $0.46Adjusted non-GAAP EBITDA of $22.2 millionAdjusted non-GAAP diluted earnings per share of $1.32
Arthur... More
